A detailed history of Slocum, Gordon & CO LLP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Slocum, Gordon & CO LLP holds 4,854 shares of BMY stock, worth $261,921. This represents 0.16% of its overall portfolio holdings.

Number of Shares
4,854
Previous 4,494 8.01%
Holding current value
$261,921
Previous $243,000 17.28%
% of portfolio
0.16%
Previous 0.19%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$40.25 - $52.99 $14,490 - $19,076
360 Added 8.01%
4,854 $201,000
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $38,784 - $46,280
800 Added 21.66%
4,494 $230,000
Q2 2023

Oct 23, 2023

BUY
$63.71 - $70.74 $235,344 - $261,313
3,694 New
3,694 $236,000
Q1 2023

Dec 14, 2023

SELL
$65.71 - $74.53 $12,484 - $14,160
-190 Reduced 5.14%
3,504 $242,000
Q4 2022

Dec 06, 2023

SELL
$68.48 - $81.09 $99,090 - $117,337
-1,447 Reduced 39.17%
2,247 $162 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Slocum, Gordon & CO LLP Portfolio

Follow Slocum, Gordon & CO LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Slocum, Gordon & CO LLP, based on Form 13F filings with the SEC.

News

Stay updated on Slocum, Gordon & CO LLP with notifications on news.